|

YL201 Clinical Trials

5 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: Platinum, Serplulimab

Pipeline

Phase 3: 1Phase 1/2: 4

Top Sponsors

  • MediLink Therapeutics (Suzhou) Co., Ltd.5

Indications

  • Cancer5
  • Lung Cancer2
  • Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma1
  • Recurrent or Metastatic Nasopharyngeal Carcinoma1
  • Nasopharyngeal Carcinoma1

Other3 trials

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 1/2
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/2

Fair Oaks, California1 trial

A Study of YL201 in Patients With Advanced Solid Tumors

002

Phase 1/2

Washington D.C., District of Columbia1 trial

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Site 1001

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.